The blood-brain barrier (BBB) is dramatically but transiently compromised in the cerebella of myelin basic protein immunized mice at least 1 week prior to the development of the paralytic phase of experimental allergic encephalomyelitis (EAE). Treatment of mice with the peroxynitrite-dependent radical scavenger uric acid (UA) during the first week after immunization blocks the early increase in cerebellar BBB permeability and the subsequent development of clinical signs of EAE. These results indicate that the early loss of BBB integrity in the cerebellum is likely to be a necessary step in the development of paralytic EAE.
Introduction
Despite the identification of a variety of factors that contribute to the pathogenesis of multiple sclerosis (MS) and its animal model experimental allergic encephalomyelitis (EAE), the precise mechanisms responsible for the development of the CNS inflammatory lesions that are characteristic of these neurodegenerative diseases remain poorly understood. Lesion formation is clearly associated with enhanced expression of a number of cytokines, chemokines, adhesion molecules and matrix metalloproteinases (MMPs) as well as the accumulation of immune/inflammatory cells in CNS tissues (reviewed Brown, 2001; Fazekas and Tabira, 2000; Hemmer et al., 2002; Imitola et al., 2005) . Free radicals including nitric oxide (NO U ) and peroxynitrite (ONOO − ), the product of NO U and superoxide, have also been implicated in lesion formation both through neurotoxicity and the induction of the changes in blood-brain barrier (BBB) integrity that are associated with immune cell invasion into CNS tissues (Cross et al., 1997; Cross et al., 1998; Hooper et al., 1997; Hooper et al., 2000; Liu et al., 2001; Scott et al., 2001; van der Veen et al., 1997) . Studies in EAE have provided considerable insight into the development of immune processes that lead to CNS pathology but information about contributory events in the CNS tissues that precede lesion formation is limited. Just as it is impossible to predict the onset of MS, or the appearance of new plaques in an existing case, it is difficult to predict whether an individual animal will develop EAE following appropriate immunization. For example, while immunized PLSJL mice all develop similar immune responses to myelin basic protein (MBP) by day 10-14 after immunization (Kean et al., 2000) , only 30-70% of the mice generally progress to exhibit clinical signs of EAE in a particular experiment (Hooper et al., 1998) . Moreover, some animals may Journal of Neuroimmunology 196 (2008) 8 -15 www.elsevier.com/locate/jneuroim
